Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | MMP8 | P22894 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19575792 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL684233 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL684796 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL12401342 | 0.82 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL21152616 | 0.81 | MMP2 (0.40) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL20023297 | 0.81 | ACE (0.32) | — | |
| SCHEMBL13223901 | 0.79 | CTSL (0.44) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL13223906 | 0.79 | CTSL (0.44) | ALDH1A1MEN1LMNAKMT2ACTSL | |
| SCHEMBL13034061 | 0.79 | CTSL (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL15851259 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | ALDH1A1 1389/4885MEN1 999/4885LMNA 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.